Mintaev Ramil R, Glazkova Dina V, Orlova Olga V, Ignatyev Georgiy M, Oksanich Alexey S, Shipulin German A, Bogoslovskaya Elena V
Federal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency, 119833 Moscow, Russia.
I. Mechnikov Research Institute of Vaccines and Sera, 105064 Moscow, Russia.
Vaccines (Basel). 2023 Apr 12;11(4):831. doi: 10.3390/vaccines11040831.
Dengue fever, an infectious disease that affects more than 100 million people every year, is a global health problem. Vaccination may be the most effective prevention strategy for the disease. However, the development of vaccines against dengue fever is complicated by the high risk of developing an antibody-dependent increase in infection. This article describes the development of an MVA-d34 vaccine against the dengue virus based on a safe and effective MVA viral vector. The DIII domains of the envelope protein (E) of the dengue virus are used as vaccine antigens, as antibodies against these domains do not cause an enhancement of infection. The use of the DIII domains of each of the four dengue virus serotypes made it possible to generate a humoral response against all four dengue virus serotypes in immunized mice. We also showed that the sera of vaccinated mice present virus-neutralizing activity against dengue serotype 2. Thus, the developed MVA-d34 vaccine is a promising candidate vaccine against dengue fever.
登革热是一种每年影响超过1亿人的传染病，是一个全球健康问题。疫苗接种可能是预防该疾病最有效的策略。然而，登革热疫苗的研发因抗体依赖性感染增强的高风险而变得复杂。本文描述了一种基于安全有效的MVA病毒载体的抗登革热病毒MVA-d34疫苗的研发。登革热病毒包膜蛋白（E）的DIII结构域用作疫苗抗原，因为针对这些结构域的抗体不会导致感染增强。使用四种登革热病毒血清型各自的DIII结构域使得在免疫小鼠中产生针对所有四种登革热病毒血清型的体液反应成为可能。我们还表明，接种疫苗小鼠的血清对登革热2型具有病毒中和活性。因此，研发的MVA-d34疫苗是一种有前景的抗登革热候选疫苗。
Zotero 插件
